Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Change in Accured Expenses (2019 - 2025)

Cyclerion Therapeutics has reported Change in Accured Expenses over the past 7 years, most recently at $85000.0 for Q3 2025.

  • Quarterly results put Change in Accured Expenses at $85000.0 for Q3 2025, up 140.48% from a year ago — trailing twelve months through Sep 2025 was $27000.0 (up 103.21% YoY), and the annual figure for FY2024 was -$515000.0, up 67.49%.
  • Change in Accured Expenses for Q3 2025 was $85000.0 at Cyclerion Therapeutics, up from -$138000.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for CYCN hit a ceiling of $462000.0 in Q2 2023 and a floor of -$3.4 million in Q1 2021.
  • Median Change in Accured Expenses over the past 5 years was -$186000.0 (2022), compared with a mean of -$362526.3.
  • Peak annual rise in Change in Accured Expenses hit 527.78% in 2023, while the deepest fall reached 636.36% in 2023.
  • Cyclerion Therapeutics' Change in Accured Expenses stood at -$281000.0 in 2021, then skyrocketed by 33.81% to -$186000.0 in 2022, then tumbled by 97.31% to -$367000.0 in 2023, then surged by 88.83% to -$41000.0 in 2024, then soared by 307.32% to $85000.0 in 2025.
  • The last three reported values for Change in Accured Expenses were $85000.0 (Q3 2025), -$138000.0 (Q2 2025), and $121000.0 (Q1 2025) per Business Quant data.